Table 1.

Effect of PDE inhibitors on AVP-dependent cAMP levels

TreatmentADPKD CellsNHK Cells
Control1.23±0.110.62±0.08
AVP8.41±1.28a16.28±2.77a
AVP+vinpocetine9.27±2.1822.29±3.77
AVP+cilostamide9.18±1.8420.35±4.07
AVP+rolipram15.20±2.57b27.04±4.06
  • ADPKD and NHK cells were treated with AVP in the absence and presence of PDE inhibitors vinpocetine (PDE1), cilostamide (PDE3), and rolipram (PDE4). cAMP amounts in picomole per monolayer (mean±SEM) were analyzed by one-way ANOVA and Student–Newman–Keuls post-tests. ADPKD cell monolayers (n=12) were from three ADPKD kidneys, and NHK cell monolayers (n=11) were from three normal kidneys.

  • a P<0.01 compared with controls.

  • b P<0.05 compared with AVP alone.